Study-related adverse events. by Benjamin R. Lewis (22279166)

“…Secondary outcome measures included the Demoralization Scale (DS-II) and the Watt’s Connectedness Scale (WCS). Adverse events (AEs) and suicidality were assessed through a 6-month follow-up. …”

Adverse cardiovascular events by immune checkpoint inhibitor. by Jennifer M. Kwan (3350321)

Subjects:

Distribution of cases and adverse events associated with metformin. by Mengsi Peng (12882734)

Subjects:

Baseline demographics and comorbidities by presence of post-treatment adverse cardiovascular events. by Jennifer M. Kwan (3350321)

Subjects:

Cox regression models for adverse cardiovascular events (ACE) and individual components of ACE. by Jennifer M. Kwan (3350321)

Subjects:

Number of adverse reaction case reports of finasteride administration at the PT level. by Xiaoling Zhong (181270)

Subjects:

Adverse event list. by Stefan Halbherr (21353882)

“…</p><p>In addition to weekly history taking, scales to measure mood, behavior, quality of life, sleepiness, non-motor symptoms of PD, and cognition were used as further secondary outcomes as well as assessing the Levodopa-Equivalent Daily Dose (LEDD). Overall, 304 adverse events (mean: 25.33; 6–75 events per patient) occurred, 267 of which were mild (mean: 22.25; 3–72 events per patient). 23 were considered related to the study treatment (0–8 events per patient). …”

Key safety measures including adverse events. by Anuja Dokras (8679261)

Four grid table. by Xiaoling Zhong (181270)

Subjects:

Flowchart depicting the selection of the study population. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the PT level (age < 18). by Xiaoling Zhong (181270)

Subjects:

Basic information and patient characteristics according to the report. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the preferred term level in the FAERS database. by Xiaoling Zhong (181270)

Subjects:

Four major algorithms used for signal detection. by Xiaoling Zhong (181270)

Subjects:

Time to onset of AEs in male and female patients receiving finasteride therapy. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the SOC level. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the SOC level by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration in female at the PT level. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration in male at the PT level. by Xiaoling Zhong (181270)

Subjects:

Signal strength of reports of finasteride administration at the PT level (age = 18-65). by Xiaoling Zhong (181270)

Subjects: